leisure time -WSS

leisure time

author：entertainment 2025-09-27 07:25:01 - browse：1

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Can sheer will power keep patients alive in their dying hours?

knowledge

focus

WSS

Doctor of U.S. President Joe Biden says he is fit for duty

CDC panel: People 65 and older should get a Covid spring booster shot

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Pfizer is about to make a big push in cancer. Will investors listen?

Medicare Advantage beneficiaries sue Humana over algorithm use

David Ricks of Eli Lilly: best biopharma CEO of 2023

Wikipedia

leisure time

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

New air purifier tech could be key to improving indoor air quality

Editas, Vertex strike deal on CRISPR

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC advisory group OKs chikungunya vaccine

Peter Hotez and the public health issue of online harassment

Medicare Advantage isn’t working — for anyone

Bright Health sells Medicare Advantage business to Molina

5 ways to address the shortage of health care workers

hotspot

STAT Madness 2024: Meet the contenders

Study fuels hope CAR

What STAT readers think about the FDA and patient advocacy

SEC charges former device maker CEO with $41 million fraud

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Medicare Advantage isn’t working — for anyone

focus

knowledge

focus

entertainment